



Tri Action Synergy
for Uncontrolled T2DM

In uncontrolled T2DM patients

^{Rx} *Diet, Exercise &*

AffOodapa[®]-GM $\frac{1}{2}$
Dapagliflozin 10mg + Glimepiride 1/2 mg + Metformin 1000 mg Tablets





Background

Managing Type-2 Diabetes Mellitus (T2DM) often requires combination therapy, but many regimens are limited by risks such as hypoglycemia and weight gain. The Metformin–Sulfonylurea combination remains the most common approach, though sulfonylureas are used both as second-line and, at times, first-line alternatives.

More recently, SGLT-2 inhibitors have emerged as advanced oral agents that lower blood sugar by blocking renal glucose reabsorption. Beyond glycemic control, they also help reduce cardiovascular risk and protect kidney function. When added to Metformin & Sulfonylureas, they provide greater efficacy than monotherapy or dual therapy alone.

Product Description

Affodapa GM is a triple therapy formulation that combines Dapagliflozin, Glimepiride, and Metformin, designed for effective management of Type-2 Diabetes Mellitus in adults

- ▶ **Affodapa GM 1:** Dapagliflozin 10 mg + Glimepiride 1 mg + Metformin (ER) 1000 mg
- ▶ **Affodapa GM 2:** Dapagliflozin 10 mg + Glimepiride 2 mg + Metformin (ER) 1000 mg

Indication

Affodapa GM is indicated as an adjunct to diet and exercise for adults with Uncontrolled Type-2 Diabetes who:

- ▶ Do not achieve sufficient glycemic control with metformin alone, or
- ▶ Initially respond to glimepiride or dapagliflozin but require additional control.

Mechanism of Action

- ▶ **Glimepiride:** Stimulates insulin release from functional pancreatic beta cells, enhancing endogenous insulin activity.
- ▶ **Metformin:** Improves glucose tolerance by reducing hepatic glucose production, limits intestinal glucose absorption, and increase peripheral glucose uptake and utilization.
- ▶ **Dapagliflozin:** Selectively inhibits SGLT-2 in the kidney, reduces glucose reabsorption and promotes glucose excretion via urine, thereby lowering blood glucose levels.

Dosage

The recommended dose is one tablet once daily, (preferably with food), or as prescribed by the doctor.

T2DM: Type-2 Diabetes Mellitus
SGLT-2: Sodium Glucose Co-transporter 2

- References:**
1. Scientific Reports volume 11, Article number: 137 (2021)
 2. Diabetes Obes Metab. 2020;22:1083–1093
 3. JAMA Cardiol. 2021 Feb 1;6(2):148–158.



1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 Tel.: 011-47589500-51 (50 lines)
Web: www.medicamen.com/lifesciences | E-mail: info@medicamenlifesciences.com

I am: _____
Call me on: _____
Mail me at: _____

2025 All rights reserved, Medicamen Lifesciences Pvt Ltd